Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARL | Q9H300 | 1/20 | 0.39 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.36 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.36 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.36 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4138404 | 0.86 | PARL (0.41) | PARLPSIP1HSD11B1ALDH1A1KMT2A | |
| SCHEMBL28268959 | 0.85 | ALDH1A1 (0.41) | ALDH1A1KMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL22265082 | 0.84 | PARL (0.40) | PARLPSIP1HSD11B1ALDH1A1KMT2A | |
| SCHEMBL3447252 | 0.83 | PSIP1 (0.45) | PARLPSIP1HSD11B1ALDH1A1ATM | |
| SCHEMBL22265192 | 0.83 | PARL (0.39) | PARLPSIP1HSD11B1ALDH1A1KMT2A | |
| SCHEMBL22265193 | 0.83 | TDP1 (0.39) | PARLPSIP1ALDH1A1ATMKMT2A | |
| SCHEMBL2057595 | 0.82 | PSIP1 (0.43) | PARLPSIP1HSD11B1ALDH1A1ATM | |
| SCHEMBL5590961 | 0.82 | PSIP1 (0.43) | PARLPSIP1HSD11B1ALDH1A1ATM | |
| SCHEMBL2270234 | 0.82 | CA1 (0.43) | PARLPSIP1HSD11B1ALDH1A1KMT2A | |
| SCHEMBL25402625 | 0.79 | HSD11B1 (0.40) | HSD11B1ALDH1A1KMT2AABCC9ABCC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760737-B2 | Process for manufacturing 4-(2,2,3,3-tetrafluoropropyl)morpholine | ADVERIO PHARM GmbH (DE) | 2023-09-19 | — | — | US | disclosed |
| US-20220089554-A1 | PROCESS FOR MANUFACTURING 4-(2,2,3,3-TETRAFLUOROPROPYL)MORPHOLINE | ADVERIO PHARMA GMBH (DE) | 2022-03-24 | — | — | US | disclosed |
| EP-3914588-A1 | PROCESS FOR MANUFACTURING 4-(2,2,3,3-TETRAFLUOROPROPYL)MORPHOLINE | Adverio Pharma GmbH (DE) | 2021-12-01 | — | — | EP | disclosed |
| CN-113272286-A | Process for preparing 4- (2,2,3, 3-tetrafluoropropyl) morpholine | 阿德弗里奥药品有限责任公司 | 2021-08-17 | — | — | CN | disclosed |
| WO-2020152010-A1 | PROCESS FOR MANUFACTURING 4-(2,2,3,3-TETRAFLUOROPROPYL)MORPHOLINE | ADVERIO PHARMA GMBH (DE) | 2020-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089554-A1 | PROCESS FOR MANUFACTURING 4-(2,2,3,3-TETRAFLUOROPROPYL)MORPHOLINE | CYP4F3, CYP4F2, TNNT2 | PARL 1536/4885PSIP1 2583/4885HSD11B1 2980/4885 |
| US-11760737-B2 | Process for manufacturing 4-(2,2,3,3-tetrafluoropropyl)morpholine | CYP4F3, CYP4F2, TNNT2 | PARL 1536/4885PSIP1 2583/4885HSD11B1 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.